In preliminary injunction proceedings initiated by Lindt & Sprüngli, the Commercial Court of the Canton of Aargau prohibited the use of a copy of Lindt’s trademark protected “Pouring Shot” logo on the packaging
OnlineDoctor has acquired A.S.S.I.S.T., an artificial intelligence (AI) developer in the field of dermatology. The acquisition marks a first in OnlineDoctor’s history and is part of its strategy to
The management buy-out (MBO) of tp, ag für technische Planungen was completed. GHR advised tp and its shareholders on corporate and tax matters. tp, ag für technische Planungen is an independent engineering company
Shareholders of the UK-based Axis Electronics (Axis) has completed the sale of their shares to SIX listed Cicor Group. Founded originally as part of an international electronics company, Axis was established in 1995 as an independent,
UBS Group successfully completed its issuance of CHF 265 million 3.375 per cent. Tier 1 Capital Notes. The Notes are «high trigger» regulatory capital instruments that are eligible to fulfil UBS Group’s Swiss going concern requirements. The
FairCap, a Germany based entrepreneurial investment company, has acquired Nyco Flexible Packaging, a Switzerland based manufacturer of advanced and sustainable packaging solutions for the food, beverage, household, personal care and healthcare industries, from Clondalkin Group,
Bank J. Safra Sarasin acquires the remaining 42.5% of the Swiss online bank zweiplus from Aabar Trading, a subsidiary of the sovereign wealth fund of Abu Dhabi. bank zweiplus will remain a FINMA-licensed company and operate
Senectovia, a provider of products and services in the field of decubitus prophylaxis and therapy, mobilisation and obesity care. The medical technology company founded in 1980 was taken over by a family office as part of
Smart Valor, a financial technology company operating a digital asset and cryptocurrency exchange, becomes the first digital assets exchange in Europe listed on Nasdaq. As a fully compliant exchange, authorised by the financial supervisory authority
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination
